Lung cancer in Bulgaria ‒ diagnosis, treatment, and factors affecting survival

Mihaylova, Zornitsa; Megdanova, V.; Petrova, V.; Petkova, D.; Fakirova, Albena; Petrova, M.V.; Asenov, R.; Kisjova, Iva; Encheva, Milena; Dinev, Hristo

doi:10.1007/s12254-015-0214-8

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these unqualified articles, five of them don’t have HR with 95% CI for survival; six of them are meeting records, while one is a letter; three of them only have conference abstracts without full texts; and one of them was written in Chinese. Finally, we obtained 12 articles, but one study had duplicated data with ours 11 , so 11 articles and our study with 4608 patients were selected for meta-analysis to explore prognostic value of PLR in lung cancer 12 13 14 15 16 17 18 19 20 21 22 . Among these included studies, one could be divided into two “sub-studies” for providing sufficient information based on two groups of patients with different stage, we named them as Xie dong1 and Xie dong2, so we thought there were 13 records in our meta-analysis for convenience 22 .…”

Section: Resultsmentioning

confidence: 99%

The Prognostic Value of PLR in Lung Cancer, a Meta-analysis Based on Results from a Large Consecutive Cohort

Ding

Pang

Shen

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Recently, many studies have been conducted to explore prognostic value of platelet to lymphocyte ratio (PLR) for patients with lung cancer, while the results remain controversial. We collected pretreatment, clinicopathological and follow-up data of 1388 lung cancer patients receiving surgery between 2006 and 2011 in our hospital, and reviewed relevant articles from Embase, Pubmed, Web of science databases, then performed a meta-analysis to clarify the relationship between PLR and prognosis of lung cancer patients. Finally, 11 articles with our study were included, results indicated elevated PLR was negatively related to overall survival (HR = 1.33, 95% CI: 1.10–1.62), but not related to progress-free survival (HR = 1.21, 95% CI: 0.97–1.49). Subgroup analysis suggested high PLR was correlated with poor survival in non-small cell lung cancer (HR = 1.43, 95% CI: 1.14–1.78), but not in small cell lung cancer (HR = 1.10, 95% CI: 0.76–1.58). Besides, for patients treated by chemotherapy or radiotherapy (HR = 1.66, 95% CI: 1.15–2.38) and patients in late stage (HR = 1.41, 95% CI: 1.19–1.68), PLR had significantly prognostic value. Additionally, the result was significant for patients when cut-off value of PLR was between 150 and 200 (HR = 1.47, 95% CI: 1.18–1.82). In Conclusion, this meta-analysis revealed that elevated PLR was associated with poor prognosis in lung cancer.

show abstract